Wijkman MO, et al. - Researchers performed this study on 124 type 2 diabetics who had insulin treatment and were randomized to liraglutide or placebo in a double-blind, placebo-controlled trial, to determine predictors of systolic blood pressure (SBP) reduction, and its correlation with weight loss and with improved glycemic control. They found a larger reduction in SBP in patients with lower mean continuous glucose monitoring (CGM) values at baseline. They also observed that there was no relation between improved hemoglobin A1c (HbA1c) during follow-up and reductions of SBP. They noted that, only with regard to diastolic blood pressure and mean CGM, liraglutide group and the placebo group had remarkably different regression coefficients. Findings revealed a direct correlation of SBP reduction with change in body weight and body mass index (BMI), but not with change in HbA1c. Liraglutid may be beneficial for some patients in terms of weight and SBP reduction.